Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

New oxygen sensor accuracy trial launches

NCT ID NCT07521735

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jul 16, 2026 · Updated 2 times

Summary

This study checks how well new Philips SpO2 sensors measure blood oxygen levels in 36 healthy adults aged 18-50. Participants will have their oxygen levels tested during rest, and results will be compared to a lab reference. The goal is to ensure the sensors are accurate for future hospital and MRI use.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Philips SpO2 sensors (M1191BL, Gen-4, MRI Gen-4, Adult SpO2 Glove, Adult SpO2 Grips) used with Philips MR400 Pro MRI Patient Monitor and IntelliVue Patient Monitor X3
What this could lead to
If successful, this could confirm that these new sensors reliably measure oxygen levels, leading to better monitoring in hospitals and MRI settings.
What could go wrong
This is a small, early-stage validation study in 36 healthy adults, not patients. Results may not apply to real-world clinical situations or people with health conditions.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

46 people

The number who actually took part.

Started

Mar 2026

Finished

Mar 2026

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

At least 36 participants considered healthy, non-smoking (or have refrained from smoking for 2 days) competent adults, ages 18 to 50 years.

Ages

18 to 50 years

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Participant must have the ability to understand and provide written informed consent. * Participant is an adult between 18-50 years of age. * Participant must be willing and able to comply with study procedures and duration. * Participant is a non-smoker or who has not smoked within 2 days prior to the study. * Male or female assigned at birth of any race. Exclusion Criteria: * Participant is considered as being morbidly obese (defined as BMI \>39.5) * Compromised circulation (i.e., Raynaud's Syndrome), injury, open wound, or physical malformation of fingers, toes, hands, ears or forehead/skull or other sensor sites which would limit the ability to test sites needed for the study. Tattoos in the optical path which would limit the ability to test sites needed for the study. (Note: Certain malformations may still allow participants to participate if the condition is noted and would not affect the sites utilized.) * Females who are pregnant * Females who are trying to get pregnant (with confirmation of positive urine pregnancy test unless the participant is known to be not of child-bearing potential) * Participants who have smoked in the last 2 days or participants who have refrained, for at least 48 hours, with COHb levels \>3% as assessed with a Masimo Radical 7 (Rainbow) * Participants with known respiratory conditions such as: (self-reported) * uncontrolled / severe asthma, * flu, * pneumonia / bronchitis, * shortness of breath / respiratory distress, * unresolved respiratory or lung surgery, * emphysema, COPD, lung disease * Recent COVID with or without hospitalization (last 2 months) * Participants with self-reported heart or cardiovascular conditions such as: (self-reported, except for blood pressure and ECG review) * high blood pressure: systolic \>140 mmHg or diastolic \>90 mmHg on 3 consecutive readings (reviewed during health screen) * have had cardiovascular surgery, except successful minor surgery without clinical symptoms (i.e., PFO, PDA) * chest pain (angina) * heart rhythms other than a normal sinus rhythm or with respiratory sinus arrhythmia (reviewed during health screen) * previous heart attack * blocked artery * unexplained shortness of breath * congestive heart failure (CHF) * history of stroke * transient ischemic attack * carotid artery disease * myocardial ischemia * myocardial infarction * cardiomyopathy * implantable active medical device such as pacemaker or automatic defibrillator * Self-reported health conditions as identified in the Health Assessment Form * diabetes, * uncontrolled thyroid disease, * kidney disease / chronic renal impairment, * history of seizures (except childhood febrile seizures), * epilepsy, * history of unexplained syncope, * recent history of frequent migraine headaches, * recent symptomatic head injury (within the last 2 months), * Cancer requiring chemotherapy, radiation, or current treatment. * Participants with known clotting disorders (self-reported) * history of bleeding disorders or personal history of prolonged bleeding from injury * history of blood clots * hemophilia * current use of blood thinner: prescription or daily use of aspirin * Sickle Cell Trait or Disease * Participants with self-reported dermatological conditions at sensor application sites * severe dermatitis * hyperkeratosis * nail fungus * Participants with severe contact allergies to standard adhesives, latex, silicone or other materials found in pulse oximetry sensors, ECG electrodes, respiration monitor electrodes or other medical sensors (self-reported) * Participants with severe allergies to iodine (only applicable if iodine is used) * Participants with severe allergies to lidocaine (or similar pharmacological agents, e.g. Novocaine) * Participants with allergies to ultrasound gel * Failure of the Perfusion Index Ulnar/Ulnar+Radial Ratio test (Ratio \<0.4) * Unwillingness or inability to remove nail polish, nail jewelry, or artificial nails from test digits. Bruised nail bed of test digits (Note: Certain bruising may still allow participants to participate if the condition is noted and would not affect the sites utilized.) * Unwillingness or inability to cut/trim fingernail(s) of test digits if determined length will interfere with correct application of the sensor. * Participant received intravascular dye within the past 48 hours (e.g. Indocyanine green, methylene blue, indiocarmine, dyes used in cardiac output monitoring) * Surgical hardware in pathway of Device Under Test * Other known health conditions should be considered upon disclosure in health assessment form. * Participants with uneven skin tone at the sensor site or at the forehead * Participants who were previously enrolled and/or included in the terminated Optimus Validation study

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Pulse oximetry are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Element Materials Technology

    Louisville, Colorado, 80027, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.